Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Amgen and Xencor Enter Option Deal to Co-Develop Xencor’s Novel Antibody for Autoimmune Diseases

By Pharmaceutical Processing | January 7, 2011

Amgen and Xencor, Inc. have announced that they will
collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually
targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical
development for the treatment of autoimmune diseases.  

Under the terms of the agreement, Amgen has the option to an
exclusive worldwide license following the completion of a pre-defined Phase 2
study. Xencor will lead all clinical development until that time. Xencor will
receive an up-front and early development milestone payments. If Amgen does
exercise its option, Amgen will assume responsibility for future development,
Xencor will receive an option-exercise fee which, combined with the up-front
and early development milestones, will total $75 million, and Xencor could
receive up to an additional $425 million in clinical, regulatory and
commercialization milestone payments.  Xencor will receive tiered
royalties on future sales of XmAb5871.

Xencor’s CD32b technology is a novel immunomodulatory
platform consisting of engineered Fc domains with selective high affinity
binding to FcyRIIb (CD32b), a receptor with dominant inhibitory activity on B
cells and other immune cells. The CD32b pathway has never been therapeutically
exploited and applied to high affinity antibodies targeting immune cells.

“XmAb5871 provides a novel approach to suppress B-cell
function which will enhance Amgen’s internal efforts in inflammatory
diseases,” said Joseph P. Miletich, M.D., Ph.D., senior vice president,
Research & Development at Amgen.  “We are delighted to have the
opportunity to partner with Xencor in exploring their novel immunomodulatory
approach.”

“Amgen’s long-time leadership in antibody development
for oncology and inflammatory diseases aligns seamlessly with Xencor’s pipeline
development,” said Bassil Dahiyat, Ph.D., chief executive officer of Xencor.
“We expect that XmAb5871 will soon become the fifth XmAb-engineered
antibody in clinical development.  This program is a testament to the
progress we’ve made expanding the XmAb platform into autoimmune disease with
our CD32b technology, which is at the core of the XmAb5871 compound. The option
deal structure allows us to continue to lead the development of XmAb5871 while
also leveraging Amgen’s experience in developing novel biologics for unmet
medical needs.”  

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE